Abstract: The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females.

Abstract: The present disclosure provides anti-SAS1B antibodies, antigen-binding fragments thereof, and antibody-drug conjugates and methods of their use. This present disclosure also provides an isolated antibody or antigen-binding portion thereof having at least one of SB antibodies binding to surface exposed SAS1B, and 6B1 antibodies identifying at least one set of cancer patients testing positive for SAS1B expression.

Abstract: The present disclosure provides anti-SAS1B antibodies, antigen-binding fragments thereof, and antibody-drug conjugates and methods of their use. This present disclosure also provides an isolated antibody or antigen-binding portion thereof having at least one of SB antibodies binding to surface exposed SAS1B, and 6B1 antibodies identifying at least one set of cancer patients testing positive for SAS1B expression.

Abstract: The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females.

Abstract: The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females.

Abstract: The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females.

Abstract: A method and device to conform with the glans penis to recover ejaculated semen completely, to prevent the loss of initial sperm rich epididymal fractions, to avoid the use of a condom for masturbation, to eliminate the multi-step transfers of semen following ejaculation that are common with current methods, and to provide a single device that contains a semen collecting chamber that fits onto a glans penis. The device provides a storage and measuring reservoir, an optional cap, and a vertical stand in one integrally formed module in a sterile pack. The device and method will have multiple uses in a variety of contexts including, but not limited thereto: in the diagnosis of infertility, in semen donation, in vitro fertilization (IVF)/intra-cytoplasmic sperm injection (ICSI) clinics, hospitals, forensic laboratories and research laboratories and will be included in kits intended for over-the-counter sperm testing devices.

Abstract: The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females.

Abstract: The present invention relates to novel egg membrane protein receptors and to methods of inhibiting the interaction of sperm proteins with egg proteins. The invention further relates to methods of preventing and inhibiting sperm-egg binding, sperm-egg fusion, and fertilization. The invention further relates to the egg membrane proteins MET and ZEP.

Abstract: The present invention provides compositions and methods useful for diagnosing cancer and for monitoring the progression and treatment of cancer, as well as targets for treating cancer. The invention provides sperm and testis associated antigens, such as the protein CABYR, as biomarkers and as targets for chemotherapy.

Abstract: Methods and compositions for identifying and isolating sperm cells from samples containing multiple cell types are described. The methods and compositions employ antibodies that specifically bind to sperm-specific antigens located on or internal to the sperm plasma membrane. A reporter molecule may be conjugated to the antibodies to aid in the detection of sperm. The antibodies may be targeted to sperm-specific antigens in the head and/or tail of sperm to facilitate the identification and isolation of sperm cells from forensic samples prepared from sexual assault evidence. Purified DNA from the isolated sperm cells can be amplified by polymerase chain reaction to assist forensic analysis in sexual assault cases.

Abstract: A method and device to conform with the glans penis to recover ejaculated semen completely, to prevent the loss of initial sperm rich epididymal fractions, to avoid the use of a condom for masturbation, to eliminate the multi-step transfers of semen following ejaculation that are common with current methods, and to provide a single device that contains a semen collecting chamber that fits onto a glans penis. The device provides a storage and measuring reservoir, an optional cap, and a vertical stand in one integrally formed module in a sterile pack.

Abstract: The present invention relates to two novel, testis-specific proteins (C19 and C23) that arc lysozyme paralogues. The proteins are believed to play a role in capacitation of sperm and the fertilization of the ovum. Therefore these compounds make ideal targets for the design of contraceptive agents. The C19 and C23 proteins can also be modified to establish lysozyme activity and the modified proteins can then be used in all applications that currently exist for lysozymes.

Abstract: The present invention is directed to a family of testis specific proteins (SLLPs) that share high sequence identity to lysozyme-C proteins. The application encompasses compositions comprising the SLLP proteins, antibodies specific for the SLLP polypeptides and the use of the SLLP polypeptides and antibodies directed to such peptides as contraceptive agents.

Abstract: The present invention relates to two novel, testis-specific proteins (C19 and C23) that are lysozyme paralogues. The proteins are believed to play a role in capacitation of sperm and the fertilization of the ovum. Therefore these compounds make ideal targets for the design of contraceptive agents. The C19 and C23 proteins can also be modified to establish lysozyme activity and the modified proteins can then be used in all applications that currently exist for lysozymes.

Abstract: The present invention relates to acidic (pI 4.0) 86 kDA isoforms of a novel, polymorphic, testis-specific protein designated calcium binding protein 86 (CBP86). This protein is tyrosine phosphorylated during in vitro capacitation and bound calcium45 on 2-D gels, the latter effect abolished by dephosphorylation with alkaline phosphatase. CBP86 localizes to the principal piece of the human sperm flagellum in association with the fibrous sheath and is the first demonstration of a sperm protein that both oligomerizes and gains calcium binding capacity in a tyrosine phosphorylation dependent manner during capacitation.

Abstract: The present invention relates to two novel, testis-specific proteins (C19 and C23) that arc lysozyme paralogues. The proteins are believed to play a role in capacitation of sperm and the fertilization of the ovum. Therefore these compounds make ideal targets for the design of contraceptive agents. The C19 and C23 proteins can also be modified to establish lysozyme activity and the modified proteins can then be used in all applications that currently exist for lysozymes.

Abstract: The present invention relates to a newly identified human soluble adenylyl cyclase and nucleic acid sequences encoding the adenylyl cyclase. The invention further relates to methods of using the adenylyl cyclase polypeptides and polynucleotides as a targets for identifying agonists and antagonists that are selective for human soluble adenylyl cyclase. Inhibitors of human soluble adenylyl cyclase can be used as contraceptive agents.